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Widespread resetting of DNA methylation
in glioblastoma-initiating cells suppresses
malignant cellular behavior
in a lineage-dependent manner
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Epigenetic changes are frequently observed in cancer. However, their role in establishing or sustaining the
malignant state has been difficult to determine due to the lack of experimental tools that enable resetting of
epigenetic abnormalities. To address this, we applied induced pluripotent stem cell (iPSC) reprogramming
techniques to invoke widespread epigenetic resetting of glioblastoma (GBM)-derived neural stem (GNS) cells.
GBM iPSCs (GiPSCs) were subsequently redifferentiated to the neural lineage to assess the impact of cancer-
specific epigenetic abnormalities on tumorigenicity. GiPSCs and their differentiating derivatives display
widespread resetting of common GBM-associated changes, such as DNA hypermethylation of promoter regions of
the cell motility regulator TES (testis-derived transcript), the tumor suppressor cyclin-dependent kinase inhibitor
1C (CDKN1C; p57KIP2), and many polycomb-repressive complex 2 (PRC2) target genes (e.g., SFRP2). Surprisingly,
despite such global epigenetic reconfiguration, GiPSC-derived neural progenitors remained highly malignant upon
xenotransplantation. Only when GiPSCs were directed to nonneural cell types did we observe sustained
expression of reactivated tumor suppressors and reduced infiltrative behavior. These data suggest that imposing an
epigenome associated with an alternative developmental lineage can suppress malignant behavior. However, in
the context of the neural lineage, widespread resetting of GBM-associated epigenetic abnormalities is not
sufficient to override the cancer genome.
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The dominant model of cancer progression is the multi-
step accumulation of genetic changes that activate proto-
oncogenes and silence tumor suppressors (Hanahan and
Weinberg 2000). However, epigenetic mechanisms can
also influence the activity of cancer-associated pathways
through their effects on transcriptional regulation. Changes
in histone modifications and noncoding RNAs have been
reported during tumorigenesis (Jones and Baylin 2007).
However, the canonical epigenetic defect in human can-
cer relates to DNAmethylation. DNA hypermethylation
at promoter regions has been functionally implicated in
the stable silencing of PRC2 (Polycomb-repressive com-
plex 2) targets and classical tumor suppressor genes
(Jones and Baylin 2007; Widschwendter et al. 2007). De-
spite these advances, a lack of experimental approaches
enabling simultaneous global restoration of a normal
DNA methylome in cancer cells has limited our ability
to assess whether methylation defects are critical drivers
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of the malignant state or, rather, secondary epiphenomena
(Baylin and Bestor 2002).
Glioblastoma (GBM) is the most prevalent and aggres-
sive form of human brain cancer. GBMs are driven by an
immature cancer stem cell population that displaysmany
characteristics of normal neural stem (NS) cells (Ward
and Dirks 2007). In vitro expansion of NS cells and GBM-
derived stem cells as primary cell lines is possible by propa-
gating them as neurospheres in suspension culture (Singh
et al. 2003; Galli et al. 2004; Lee et al. 2006) or in adherent
culture conditions (Pollard et al. 2009). Adherent GBM
neural stem (GNS) cells retain stem cell characteristics and
are tumor-initiating following xenotransplantation, recapit-
ulating key features of the human disease such as extensive
infiltration of surrounding brain regions (Pollard et al. 2009).
Patterns of DNA methylation in primary GBM speci-
mens have recently been cataloged and include disrup-
tions at many novel candidate tumor suppressors, such as
the cell motility regulator TES (testis-derived transcript)
as well asmany polycomb repressor complex 2 (PRC2) target
genes (Martinez et al. 2009). Silencing of tumor suppressors
associated with ‘‘classic’’ genetically altered pathways (i.e.,
P53, RTK/PI3K, and CDK/RB) is not frequently observed.
Epigenetic reprogramming of genetically normal hu-
man somatic cells to a pluripotent stem cell state has
recently been achieved through the expression of defined
sets of transcription factors (Takahashi et al. 2007). This
seminal work demonstrated that the epigenetic restric-
tions imposed by normal development are experimen-
tally reversible using simple methods. More recently, it
has been shown that transcription factor-mediated re-
programming can also be applied to human cancer cell
lines (Carette et al. 2010; Miyoshi et al. 2010). However,
several important issues remain unclear. First, can hu-
man cancer cells with highly aneuploid genomes be suc-
cessfully reprogrammed? Second, if so, are cancer-specific
epigenetic abnormalities erased? Third, does removal of
these abnormal marks correlate with transcriptional
changes and suppression of malignant behavior? Fourth,
are these effects independent of the cell identity and
developmental epigenome? In this study, we address these
issues and demonstrate that transcription factor-mediated
nuclear reprogramming can enable widespread resetting of
cancer-specific DNA methylation marks in GNS cells.
This enabled us to assess the relative contribution of the
cancer epigenome to malignant cellular behavior.
Results
GNS cells can generate induced pluripotent stem
cell (iPSC)-like colonies
We sought to identify GNS cell lines thatmight be readily
reprogrammed in order to explore the functional conse-
quences of resetting GBM-associated DNA methylation
defects. Consistent with our previous studies, we con-
firmed that a panel of 14 GNS cell lines (derived from
independent tumor specimens) express high levels of SOX2
and C-MYC but lack expression of the pluripotency-
associated factors OCT4 and NANOG (Fig. 1A; Supple-
mental Fig. 1A–D). We therefore reasoned that some
of these lines might be reprogrammable to pluripotency
through delivery of only two transcription factors,OCT4
and KLF4, as has been reported for mouse NS cells (Kim
et al. 2008). This strategy would enable us to avoid exog-
enous expression of C-MYC.
We used the piggyBac transposon system to efficiently
deliver excisable vectors PB-OCT4 and PB-KLF4 to GNS
cell cultures and the genetically normal human NS cell
line CB660 (Fig. 1B; Kaji et al. 2009). Remarkably, despite
karyotypic abnormalities in GNS cells, seven of the 14
GNS cell lines tested gave rise to iPSC-like colonies at an
efficiency similar to normal NS cells (Fig. 1C; Supple-
mental Table 1), and four of these could be continuously
expanded (G2, G7, G26, and G144). iPSC clones derived
from G7 and G26 showed consistent up-regulation of the
pluripotency marker NANOG (>1000-fold) and down-
regulation of the neural marker GFAP (>1000-fold) (Fig.
1D; Supplemental Fig. 1E).
To assess whether this indicated acquisition of an iPSC-
like phenotype, we determined expression levels of plu-
ripotency markers using the TaqMan low-density array
(TLDA) human pluripotency microfluidic cards (Applied
Biosystems). Cluster analysis confirmed that iG7 and iG26
expressedmarkers similar to human embryonic stem cells
(hESCs) and control iPSCs (iCB660), whereas iG144 and
iG2 appeared incompletely reprogrammed (Fig. 1E; Sup-
plemental Fig. 1F). GNS cells that were directly replated
into ESC culture medium on feeder cells (without transfec-
tion) never showed up-regulation of pluripotency markers
(Fig. 1D). iG7 and iG26 colonies are immunopositive
for the hESC surface markers Tra1-60, Tra1-81, SSEA4,
Tra2-49, and Tra2-54 and show a strong nuclear NANOG
signal at levels similar to control iPSCs (Fig. 2A). Thus,
iG7 and iG26 represent GBM cells reprogrammed to an
iPSC-like state (GBM iPSCs [GiPSCs]). Six clonal GiPSCs
were analyzed in greater detail to explore the effects of
reprogramming on the cancer epigenome (three indepen-
dent lines from both G7 and G26; iG7-1, iG7-2, and iG7-3;
iG26-1, iG26-2, and iG26-3).
GiPSCs retain GBM genomes but display
a transcriptional profile similar to ESCs
We next analyzed the genetic disruptions of the parental
tumor cells using SNP arrays to confirm that they possess
a genome typical of GBM. The spectrum of common
genetic lesions underlying GBM is well established
(Cancer Genome Atlas Research Network 2008). We
identified in G7 and G26 many hallmark genetic alter-
ations associated with GBM, including copy number
increases of chromosomes 7, 19, and 20 and loss of chromo-
somes 13, 14, and 15 (Fig. 2B,C). G7 harbors a local 400-kb
deletion at the CDKN2A (p16) locus, while G26 contains
a mutation in the TP53 gene (R248Q) commonly ob-
served in GBM (Supplemental Fig. 2B; data not shown).
Gene expression profiling of G7 and G26 indicates that
they are representative of different GBM subtypes (Verhaak
et al. 2010), ‘‘proneural/classical’’ and ‘‘mesenchymal,’’
respectively (E Johnstone and P Bertone, pers. comm.; data
GNS cell reprogramming
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Figure 1. GNS cells can be converted to an iPSC-
like state. (A) GNS cell lines G7 and G26 were
established from tumor samples obtained from
two different patients. (Left panels) Original tu-
mors show typical GBM histopathology (H&E) and
GFAP immunoreactivity. G7 and G26 grow as
adherent cell lines and are positive for the imma-
ture neural progenitor markers SOX2 and NESTIN.
(Right panels) Upon xenotransplantation, they
form tumors similar to the original patient tumor.
(B) Strategy used for epigenetic reprogramming of
GNS cells. Cells (2 3 106 to 6 3 106) were trans-
fected with piggyBac vectors (KLF4 and OCT4
driven by a CAG promoter). Hygromycin selec-
tion was applied for at least 3 wk. Medium was
changed to hESC condition after 1 wk. (C) Colo-
nies resembling typical hESC colonies emerged
after 4–7 wk for iG7, iG26, and control NS cells
(iCB660). iG2 and iG144 were less well defined.
Shown are typical examples after clonal colony
picking and initial passaging (P3). (D) qRT–PCR for
the critical pluripotency marker gene NANOG
and the neural marker gene GFAP. Following re-
programming, these genes are activated and sup-
pressed, respectively, and reach levels similar to
control iPSCs or hESCs. SOX2 is expressed by
ESCs, iPSCs, and NS cells. Levels were normalized
to GAPDH. RNAwas derived from iPSC andGiPSC
culture passages 4–8. (E) Correlation analysis of
hESCs, iPSCs, NS cells, GNS cells, and GiPSCs,
based on expression levels of 90 markers present
on the TLDA (Applied Biosystems) pluripotency
panel. iG7 and iG26 are more similar to iPSCs and
hESCs than to corresponding parental GNS cells
or normal NS cells (CB660). iG2 and iG144 likely
represent incompletely reprogrammed lines and
failed to correlate with iPSCs/hESCs. RNA was
derived from iPSC and GiPSC culture passages
4–8. See also Supplemental Figure 1.
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Figure 2. Gene expression profiling and marker analysis confirms that iG7 and iG26 are reprogrammed to a hESC/iPSC state. (A)
Immunocytochemistry for pluripotency marker NANOG and cell surface markers (SSEA4, TRA1-60, TRA2-49, TRA1-81, and TRA2-
54). All tested iG7 and iG26 clonal cell lines (iG7-1, iG7-2, iG7-3; iG26-1, iG26-2, and iG26-3; P4–P10) were immunopositive for these
pluripotency markers (iG7-1 and iG26-1 are shown), whereas parental GNS lines G7 and G26 were negative. SSEA4 immunostaining is
shown in live cells. (B,C) Genomic analysis using Affymetrix SNP 6.0 microarrays for GNS cells (red) and their reprogrammed
derivatives (GiPSCs, P8–P12; blue and green) identifies many hallmark genetic changes common to GBM, such as amplification of
chromosomes 7, 19, and 20 (arrows) and losses of chromosomes 13, 14, and 15. G7 and iG7 also display a 400-kb deletion that includes
CDKN2A and CDKN2B (small arrow). (D,E) PCA of global gene expression (D; see also Supplemental Fig. 2A) and hierarchical
clustering (E) of the 50 most significantly differentially expressed genes for normal NS cells and GNS cells (CB660, G7, and G26), hESCs
and two clonal GiPSCs (iG7-1, iG7-2; iG26-1, and iG26-2), and iPSCs (iCB660) confirms that iG7 and iG26 are extensively
reprogrammed to an ESC-like state. Analyzed iPSCs and GiPSCs were between passages 6 and 11.
not shown). Neither harbored IDH1 mutations that are
characteristic of secondary GBMs or significant DNA
hypermethylation at promoters commonly silenced in
glioma-CpG island methylator phenotype (G-CIMP)
tumors (Supplemental Figs. 2B, 3; Noushmehr et al.
2010). Together, these data support the original patient
tumor diagnoses for G7 andG26 as primaryGBM (Fig. 1A).
To determine the extent of reprogramming in GiPSCs,
we carried out global transcriptome analyses. We assessed
mRNA expression in iG7, iG26, and iCB660; the corre-
sponding parental lines G7, G26, and CB660; and the hESC
line Edi-2 as a comparative reference (Falk et al. 2012).
Principal component analysis (PCA) of global expression
and hierarchical clustering of differentially expressed
genes indicates that all GiPSCs undergo dramatic tran-
scriptional resetting and acquire a gene expression pat-
tern closer to normal human iPSCs and ESCs than to NS
cells (Fig. 2D,E; Supplemental Fig. 2A). Importantly, the
patterns of structural chromosomal changes in parental
GNS cells were largely retained through the reprogram-
ming process in the GiPSCs (Fig. 2B,C), indicating that
GiPSCs did not display significant genomic instability
through the experimental procedure.
GNS cells display aberrant DNA methylation marks
that are frequently observed in the human disease
To characterize cancer-specific DNA methylation abnor-
malities, we initially performed DNA methylation pro-
filing using the InfiniumHumanMethylation27 BeadChip
(Illumina). This array interrogates the DNA methyla-
tion state at CpG islands and promoters associated with
;14,000 genes, providing a broad survey of affected loci.
We comparedmethylation levels of GNS cells andNS cells
to identify cancer-specific methylation variable positions
(cMVPs) (Fig. 3A,B; Supplemental Fig. 2C). A total of 691
cMVPs were found between GNS cells (G26 and G7) and
NS cells (252 hypomethylated and 439 hypermethylated)
(Supplemental Table 2).
In primary GBMs, methylation changes are rare at
tumor suppressors within the ‘‘classic’’ genetically dis-
rupted CDK/RB, RTK, and P53 signaling pathways. Instead,
hypermethylation is frequently detected at noncanonical
genes/pathways, such as PRC2 targets (Widschwendter
et al. 2007; Martinez et al. 2009). Consistent with these
data, promoter hypermethylation of the tumor suppres-
sor genes PTEN and TP53 was not detected in G7 or G26
or in other tested GNS cell lines. We noted a high pro-
portion of PRC2 target genes in the set of cMVPs (22.1%
[G7] and 12.1% [G26]; P = 0.0001). GNS cell-specific DNA
hypermethylation also included the tumor suppressor
genes cyclin-dependent kinase inhibitor 1C, (CDKN1C,
encoding p57KIP2) and TES. Loss of CDKN1C expression
is a frequent event in a large variety of tumors, including
gliomas (Christensen et al. 2011), and is often accompa-
nied by DNA hypermethylation (Kavanagh and Joseph
2011). TES is expressed in a wide range of adult human
tissues, including brain (Tatarelli et al. 2000), and has been
previously shown to inhibit tumorigenicity of human
cancer cell lines (Tobias et al. 2001). DNAhypermethylation
of the TES promoter is one of themost frequent epigenetic
disruptions in primary GBM (;60% of cases) (Mueller
et al. 2007; Martinez et al. 2009; Christensen et al. 2011)
and is also observed in other human cancers (Qiu et al.
2010; Weeks et al. 2010). We analyzed methylation pro-
files generated for 67 GBM samples by The Cancer
Genome Atlas (TCGA) project. This revealed that TES
hypermethylation significantly associates with patient
survival (log rank P-value = 0.00232) and loss of TES
expression (data not shown). Thus, patterns of DNA
methylation in G7 and G26 faithfully mirror the human
disease and include some of the most common epigenetic
anomalies observed in primary GBM tumors.
To determine whether hypermethylation of TES and
CDKN1C promoter regions correlated with transcrip-
tional silencing in GNS cells (G7 and G26) we performed
immunoblotting (Fig. 3C). While CDKN1C showed vari-
able expression acrossGNS cell lines,TESwas fully silenced
in both GNS cell lines and was also undetectable in 10
additional cells lines assayed (Fig. 3C). Both genes were
significantly down-regulated in G7 and G26 when com-
pared with normal NS cells. These data, together with
our recent expression profiling analysis (Engstro¨m et al.
2012), identify TES as one of the most consistently down-
regulated genes in GNS cells. In keeping with their pre-
viously described functions, we found that exogenous
expression of CDKN1C in G7 cells reduces cellular
growth, while expression of TES reduces cellular motility
(Supplemental Fig. 4).
GNS cell reprogramming involves widespread resetting
of DNA methylation, including cancer-specific marks
We next assessed whether the reprogramming machinery
would be able to reset any of the above-described cMVPs.
A hallmark of successful transcription factor-based re-
programming is the removal of epigenetic restrictions,
such as the promoter-specific DNAmethylation ofOCT4
and NANOG. As expected, the cancer cell lines G7 and
G26, similarly to other somatic cells, showed pronounced
DNA hypermethylation on CpG sites proximal to the
OCT4 and NANOG transcriptional start sites (Fig. 3D).
Coincident with transcriptional activation, these specific
marks were erased during global reconfiguration of DNA
methylation that takes place during the reprogramming
process. These changes were largely consistent across
profiles from clonal GiPSCs (Fig. 3E–H). In accordance
with lineage reprogramming, the glial lineage marker
GFAP was hypermethylated in both iPSCs and GiPSCs
and also exhibited concomitant silencing of gene expres-
sion during reprogramming (Fig. 3E–H). Interestingly, the
majority of the cMVPs identified in both G7 and G26
could be reset (450 of 691; 334 originally hypermethylated
in GNS, and 116 originally hypomethylated in GNS),
suggesting that these were not permanently imposed
by the underlying genetic pathways. Hypermethylated
CDKN1C and TES loci were demethylated during reprog-
ramming, and this was validated by independent pyrose-
quencing (Supplemental Fig. 2D,E). These results confirm
that aneuploid GNS cells can be reprogrammed using
Stricker et al.
658 GENES & DEVELOPMENT
Figure 3. GNS cells possess epigenetic anomalies common in GBM that can be reset following reprogramming of GNS cells. (A,B)
Scatter plots depicting percentage of DNA methylation changes identified using Infinium Human Methylation27 BeadChip arrays
(Illumina, Inc.). Each dot represents a distinct CpG site. cMVPs hypermethylated in both G7 and G26 appear in blue, and
hypomethylated loci are in green. Normal NS cells (CB660) versus either G7 or G26 identify tumor-specific methylation changes on
genes such as CDKN1C (p57KIP2) and TES, which were hypermethylated in both parental GNS lines (see also Supplemental Fig. 2). (C)
Immunoblotting showing reduced expression of tumor suppressor genes TES (in all tested GNS lines) and CDKN1C (in several GNS
lines, including G7 and G26) when compared with normal NS cells CB660 and CB152. (D) DNA methylation analysis of theOCT4 and
NANOG promoters using pyrosequencing. An average methylation level of >50% is depicted as a black circle, while levels <50% are
shown as white circles. GNS cells contain extensive DNA methylation at both promoters, and these are removed following
reprogramming. Numbers are percentage of average DNA methylation at the OCT-4 and NANOG promoters. (E–H) Scatter plots
depicting DNA methylation levels (percentage) analyzed with Infinium Human Methylation27 BeadChip arrays (Illumina, Inc.). Each
dot represents a distinct CpG site. cMVPs hypermethylated in both G7 and G26 appear in blue, and hypomethylated cMVPs appear in
green. (E,F) iG7-1(GiPSC) versus G7 (GNS) and iG26-1 (GiPSC) versus G26 (GNS) illustrate extensive changes in methylation patterns
after reprogramming. (G,H) iG7-1 versus iG7-2 and iG26-1 versus iG26-2 illustrate similarities between individual GiPSC clonal lines.
Analyzed GiPSC clones were between passages 6 and 11.
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only two transcription factors and that associated epige-
netic changes include erasure of abnormal GBM-associ-
ated patterns of DNA methylation.
GiPSCs generate immature multilineage teratomas
in vivo
To test whether GiPSCs could engage in differentiation
programs, iCB660, iG7, and iG26 cells were injected
either subcutaneously or into the kidney capsules of
NOD/SCID mice. In each case, compact and noninfiltra-
tive tumors formed within 4–7 wk with macroscopic
appearance as teratomas (iCB660, five of six; iG7, eight
of eight; iG26, eight of nine) (Fig. 4A). As expected, tera-
tomas did not form following injection of parental G7 and
G26, and only glioma-like growths emerged (four of six
and three of six).
Teratoma formation is an intrinsic property of plurip-
otent cells and can be used to assess differentiation
potential. Histological analysis (haematoxylin and eosin
[H&E] staining) and immunohistochemistry confirmed
that in contrast to parental GNS cells, all GiPSC-derived
tumors displayed more complex patterns of differentia-
tion, including regions representative of a variety of tissue
types of all three germ layers (Fig. 4B; Supplemental Fig.
5A). These included glandular endodermal structures
(CEA+), mesoderm (muscle and cartilage S100+), non-
neural ectoderm (hair follicle and Cam5.2+), and neural
rosettes (Nestin+) (Fig. 4B; Supplemental Fig. 5A). How-
ever, despite the presence of distinct tissue types, most of
the tumor mass comprised densely packed cells with
immature histological features that included many more
mitotic figures or Ki67- or PHH3-immunopositive cells
than control teratomas (Fig. 4C; Supplemental Fig. 5C,D).
OCT4 expression was only detected in a small sub-
population of teratoma cells at a frequency similar to con-
trol iPSCs, ruling out these tumors as malignant terato-
carcinomas (Supplemental Fig. 5B). However, in both iG7
and iG26 teratomas, the majority of cells expressed the
Figure 4. GiPSCs form multilineage teratomas in vivo. (A) Appearance of teratoma-like tumors generated following transplantation of
GiPSCs into the right kidney capsule (iG7 and iG26, P8–P11). (L) Left control kidney; (R) right control kidney. iG7 and iG26 tumors
were similar in macroscopic appearance to normal iPSC-derived tumors (B) iG7 and iG26 gave rise to immature teratomas. Examples of
immature neural-like rosettes (H&E; iG7, bottom panel; iG26, top panel) as well as more differentiated nonneural tissues such as
mesenchymal cartilaginous differentiation (H&E; iG7, top panel) muscle (mesoderm; H&E; iG26, bottom panel), glandular structures
(endoderm and CEA+) and nonneural ectoderm (hair follicle CAM5.2+). Similar results were obtained for tumors derived from both
kidney capsule and subcutaneous injections. (Top panels) Brain transplantation of iG7 also gave rise to immature teratomas with
regions of nonneural tissues. (C) Mitotic markers Ki67 and phospho-histone H3 (PPH3) are observed at higher frequency in GiPSC
tumors than control iPSCs. (D) Teratomas contain CDKN1C- and TES-expressing tissues.
Stricker et al.
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neural progenitor marker Nestin and Ki67 (Supplemental
Fig. 5B). Thus, we found that GiPSCs are not ‘‘trapped’’ in
the iPSC state and can engage in both neural and non-
neural differentiation. AlthoughGiPSCs can displaymulti-
lineage differentiation, they are biased toward the neural
lineage and remain highly proliferative.
Transcription of TES and CDKN1C can be activated
following epigenetic resetting
In teratomas, TES and CDKN1C protein expression were
typically detected within regions that also contained the
nonneural epithelial marker Cam5.2 (Fig. 4D). These re-
sults suggest that despite widespread resetting of DNA
methylation marks in the GiPSCs, re-expression of pre-
viously silenced tumor suppressors may be lineage-
specific, and neural progenitors may continue to display
unconstrained proliferation. To explore this further, we
assessed tumor suppressor expression during in vitro dif-
ferentiation to neural and nonneural lineages.
Either neural or nonneural in vitro differentiation pro-
tocols resulted in down-regulation of both mRNA and
protein for the pluripotency markers NANOG and OCT4
with kinetics similar to control iPSCs (Fig. 5A; Supple-
mental Fig. 5E). To determine whether removal of abnor-
mal DNA methylation at tumor suppressor genes corre-
lated with re-expression of the mRNA and protein, we
performed immunostaining, immunoblotting, and quan-
titative RT–PCR (qRT–PCR) for tumor suppressors TES
and CDKN1C. We confirmed activation of gene expres-
sion for both genes within the differentiating population
of GiPSCs and iPSCs (Fig. 5B,C). However, it was also
evident that only a subpopulation of cells were immuno-
positive, suggesting that transcriptional regulation of
tumor suppressors is strongly influenced by either de-
velopmental lineage or extent of differentiation.
Figure 5. Demethylated tumor suppressor genes can be transcriptionally activated after reprogramming. (A) Immunocytochemistry
for the pluripotency markers NANOG and OCT4 before and after in vitro differentiation to EBs. iG7 and iG26 lines are immuno-
positive for NANOG and OCT4, while the parental GNS lines G7 and G26 are not. NANOG and OCT4 immunoreactivity was down-
regulated following differentiation. (B,C) Immunostaining and immunoblotting, respectively, show activation of previously silenced
tumor suppressor genes TES and CDKN1C during EB differentiation. (D,E) Ki67 immunocytochemistry was used to score proliferating
cells in EB differentiations (10-d + 7-d serum-containing medium) of GiPSC lines and revealed a significant and consistent increase in
numbers of cycling cells between GiPSCs and normal iPSCs (iCB660) (P = 8–14). (*) P < 0.03, Student’s t-test. See also Supplemental
Figure 5.
GNS cell reprogramming
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Notably, differentiating GiPSC cultures formed more
frequent and larger embryoid bodies (EBs) than normal
iPSCs, with significantly more Ki67-immunopositive
cells (more than twofold) (Fig. 5D,E). These data, together
with the teratoma assays, suggested that despite epige-
netic resetting, the progeny of GiPSCs were not readily
able to exit cell cycle and terminally differentiate.
Neural progenitors can be isolated and expanded
from differentiating GiPSC cultures
To rigorously assess the functional consequence of re-
setting cMVPs, we pursued in-depth functional charac-
terization of one GNS cell line (G7) plus two independent
GiPSC derivatives (iG7-1 and iG7-2) and four differenti-
ated cultures derived from those (see below). We first
differentiated GiPSCs in vitro to produce uniform cul-
tures of NS cells (Pollard et al. 2009), as GNS cells share
many characteristics of this cell type. Upon plating in
serum-free neural induction medium, GiPSCs underwent
rapid morphological changes and, within 7 d, expressed
the early neuroepithelial marker PAX6 by qRT–PCR and
immunostaining (Supplemental Fig. 5G,H). Neural differ-
entiating cultures of iG7 could be captured and expanded
as homogenous populations of neural progenitors (Fig.
6A). Within two to three passages, these cultures (desig-
nated N-iG7-1 and N-iG7-2) acquired the morphology
typical of both normal NS cell cultures and parental
G7 cells and uniformly expressed NS cell markers (e.g.,
NESTIN and BLBP) but not pluripotency-associated
markers (e.g., NANOG and OCT4) (Fig. 6C,D). NS cell
identity was confirmed following qRT–PCR analysis of
189 NS cell markers using custom TLDAs (Fig. 6E; Falk
et al. 2012).
To perform more comprehensive and higher-resolution
methylation analysis in the G7 line and its derivatives,
we profiled DNA methylation with Infinium Human
Methylation 450K BeadChip arrays (Illumina). This en-
abled widespread assessment of the density and distribu-
tion of DNA methylation, including putative regulatory
sites at CpG islands, shores, and shelves. Comparison of
three normal NS cell lines (CB660, CB1130, and CB152)
to G7 revealed 60,977 cMVPs, of which 77% (47,103) were
hypermethylated and 23% (13,876) were hypomethylated.
Permutation testing showed a significant enrichment (P =
<0.0001) for cMVPs in regulatory regions, with >61% of
cMVPs being located in CpG islands or CpG island shores.
Assessment of patterns of methylation in iG7 identi-
fied epigenetic resetting at >44% of all cMVPs genome-
wide (55% of regulatory regions such as CpG islands,
island shores, and shelves). These data identified hyper-
methylated loci in G7 that were removed in iG7 and
confirmed our earlier observations for TES andCDKN1C.
Multiple CpGs associated with the TES transcription
start site and at a region downstream from the CDKN1C
transcription start site were identified (Supplemental Fig.
6D). We also confirmed the association of cMVPs with
PRC2 target genes, which was found to be highly signif-
icant by gene set enrichment analysis (P < 1.11 3 1016).
Remarkably, 85% (559) of PRC2 target genes were found
to be associated with cMVPs. As expected, the vast
majority (92%) of these cMVPs were hypermethylated
in the cancer cells. Over half (53%) of PRC2 target genes
are associated with cMVPs that become significantly
demethylated during reprogramming (e.g., SFRP2, a nega-
tive regulator of Wnt signaling that is often a target of
hypermethylation in cancer) (Supplemental Fig. 6C,D;
Suzuki et al. 2004).
We next assessed whether epigenetic resetting of
cMVPs was stable upon redifferentiation of GiPSCs to
the NS cell type. Surprisingly, the majority (27,105, 83%)
of normalized cMVPs persisted following differentiation
of iG7 to NS cells, suggesting that cancer-related cMVPs
are not immediately reacquired in the context of NS cell
state as a result of the genetic defects in these cells (Fig.
6F). A similar proportion (80%) of PRC2 target cMVPs
was stably maintained in the reset state, including SFRP2
(Supplemental Fig. 6C,D). While the transcription start
site of TES remained demethylated during differentiation,
a minority of cMVPs reacquired methylation during dif-
ferentiation in vitro, including CDKN1C (Supplemental
Fig. 6D). Together, these results indicate that epigenetic
reconfiguration through iPSC reprogramming can be highly
stable but suggest that certain loci may be specifically
vulnerable to reacquisition of aberrant DNAmethylation.
GiPSC-derived neural progenitors remain highly
malignant despite epigenetic resetting
We next tested the tumor initiation potential of N-iG7 to
determine the functional significance of the experimental
resetting of the >25,000 cMVPs. To assess tumorigenicity,
a cohort of mice was injected with 100,000 cells (either
G7 or N-iG7-1; n = 18) (Fig. 6B). Surprisingly, in all cases,
tumors emerged with kinetics similar to those of pre-
viously studied GNS cell lines (Pollard et al. 2009). No
significant difference in overall survival between G7- and
N-iG7-transplanted mice was observed (Fig. 6G). Tumor
cells expressed the NS cell marker NESTIN and similar
levels of the mitotic marker Ki67 as tumors originating
from parental cell cultures (G7, 12.0%6 0.028%;N-iG7-1,
12.7% 6 0.036%) (Fig. 6H). G7 and N-iG7 tumors were
indistinguishable in their infiltrative behavior and typi-
cally crossed the midline to the contralateral side via the
corpus callosum (G7, five of six; N-iG7-1, three of four;
N-iG7-2, three of three) (Fig. 6H). These results suggest
that the widespread resetting of cMVPs alone is not suffi-
cient to alter malignant behavior of GBM tumor-initiating
cells.
GiPSC-derived mesodermal progenitors are less
malignant
To test whether the malignant features of these cells are
entirely defined by genetic alterations or, alternatively,
might be suppressed by imposing more extensive epige-
netic changes, we directed iG7 cells into a nonneural lin-
eage in vitro. We derived homogeneous cultures of meso-
dermal progenitors from two independent iG7 clones
(designated M-iG7-1 and M-iG7-2) through expansion of
differentiating EBs in serum-containing medium (Supple-
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Figure 6. GiPSC-derived neural progenitors remain malignant. Neural progenitors (N-iG7-1 and N-iG7-2) were generated by in vitro
differentiation of GiPSCs (P12–P14) (A) and injected in the striatum of adult mice (B). Immunostaining (C), immunoblotting (D), and
correlation analysis (E) of the expression of 189 NS cell markers using qRT–PCR on custom TLDAs. NS cells (CB660, CB541, and
CB192), GNS cells (G7 and G26), GiPSCs (iG7-1 and iG7-2), and neural (N-iG7-1 and N-iG7-2) and nonneural progeny of GiPSCs
(M-iG7-1 and M-iG72) show that neural differentiated GiPSC cultures express neural markers at levels comparable with G7. (F)
Quantification and correlation of reprogrammed cMVPs. A majority (80% and 83%) of the normalized cMVPs persist in differentiating
GiPSCs (N-iG7 and M-iG7). (G) Kaplan-Meier blot depicting the survival of a cohort of 18 adult mice that had 100,000 G7 or N-iG7 cells
injected into the striatum. (H) Coronal sections of typical examples of forebrains from mice injected with 100,000 G7 or N-iG7-1 cells
after 18 wk. (IS) Injection site; (CI) contralateral side. Immunohistochemistry for human Nestin (hNestin) and Ki67 indicates that
N-iG7 cells are highly proliferative and disperse widely from the injection site. Similarly to G7, N-iG7 cells infiltrated the contralateral
side of the brain in most cases.
mental Fig. 5F). These cells expressed T/Brachyury during
the mesodermal differentiation process, later adopted
a uniform morphology, and expressed varying levels of
nonneural epithelial markers keratins 7 and 8 (Cam5.2)
while silencing neural lineage genes (Fig. 7A). Gene
ontology analysis indicated a mesodermal/cartilage pro-
genitor identity for M-iG7 (Fig. 7B; Supplemental Table
4). The majority of normalized cMVPs persisted follow-
ing mesodermal differentiation of iG7 to M-G7 (75%
global and 83% PRC2 targets), suggesting that cMVPs are
not immediately reacquired following differentiation
(Fig. 6F; Supplemental Fig. 6C).
The continued proliferation and homogeneity of M-iG7
offered the opportunity to assess the functional conse-
quences of imposing an alternative developmental epi-
genome. Thus, we transplantedM-iG7 cells into the adult
mouse brain to determine whether tumor development
would be suppressed. All recipients survived until ;18
wk, a time point at which mice injected with parental
GNS cells had succumbed. Brains were harvested, and
following histological analysis, we identified compact
tumors that stained positive for alcian blue, indicative
of cartilaginous tissue (Fig. 7C,D; Supplemental Fig. 6E).
Interestingly, these tumors were benign and in all cases
failed to infiltrate the surrounding brain (16 of 16) (Fig.
7C). Two mice in this cohort were left unprocessed and
remained asymptomatic for >6 mo. In contrast to N-iG7,
the mesodermal M-iG7 cultures and tumors were able to
sustain expression of TES and CDKN1C mRNA and
protein (Fig. 7D–F; Supplemental Fig. 6F).
To analyze key expression changes after reprogram-
ming, we assayed a panel of 90 commonly misregulated
or functionally relevant genes in GBM by qRT–PCR using
custom-designed TaqMan microfluidic arrays (Engstro¨m
et al. 2012). Thirty-six of these show expression differ-
ences (log2 > 2.5 or log2 < 2.5) between G7 and normal
NS cells (CB660 and CB152) (Supplemental Fig. 7A,B).
Eight of these 35 genes show a significant accumula-
tion of cMVPs at the associated CpG island (HOXD10,
PDGFRA, OLIG2, TERT, CCND2, FBLN2, IRX2, and
TES). cMVPs at TES, CCND2, and IRX2 were reset in
N-iG7 cells, but expression levels did not return to those
observed inNS cells. cMVPs atTES,CCND2, and PDGFRA
were reset in M-iG7 cells and were accompanied by a res-
toration of expression patterns (Supplemental Fig. 7A,B).
Taken together, our results indicate that in vitro manip-
ulations inducing an alternative developmental lineage,
with accompanying changes to the developmental epi-
genome and resetting of cancer-specific epigenetic abnor-
malities, are able to suppress malignant cellular behavior.
Thus, the re-expression of demethylated tumor suppres-
sor genes is profoundly influenced by the specific develop-
mental lineage of the tumor cell.
Discussion
In this study, we demonstrated that iPSC reprogramming
techniques can be successfully applied to highly aneuploid
GBM cells. Exogenous expression of two reprogramming
factors, OCT4 and KLF4, leads to conversion of malignant
GNS cells to an iPSC-like state, and this is accompanied by
erasure of a large proportion of GBM-associated cMVPs.
Steering these reprogrammed cells along neural and me-
sodermal lineages has enabled us to assess for the first time
the contribution of both cancer-specific epimutations and
the developmental epigenome to the malignant properties
of GBM-initiating cells.
We focused our analysis onDNAmethylation, as this is
the most commonly studied epigenetic mark in cancer
biology, and DNA hypermethylation at promoter regions
is the canonical example of an epimutation. Although
demethylating agents, such as 5-azacytidine, have been
widely used to study DNA methylation, these are toxic
and lead to nonspecific global loss of DNA methylation,
genomic instability, and loss of imprinting (Rizwana and
Hahn 1998; Holm et al. 2005). This makes it challenging
to interpret treatment-induced changes in cellular phe-
notypes. Thus, it has remained unclear whether global
resetting of aberrant DNA methylation would be suffi-
cient to restore normal cellular behavior and inhibit tu-
morigenicity of malignant cancer cells.
Our comparison of GNS cells with genetically normal
NS cells identified >60,000 differentially methylated
sites. Importantly, the identified sites of aberrant DNA
methylation in G7 and G26 are disease-relevant and in-
clude some of the most common epigenetic anomalies
associated with primary GBM tumors. Hypermethylation
of PRC2 target genes andCDKN1C has been described for
many human cancers (Schlesinger et al. 2007; Bennett
et al. 2009; Fourkala et al. 2010; Avissar-Whiting et al.
2011). Hypermethylation of TES is among the most
prevalent epigenetic alterations to have been reported in
GBM (Martinez et al. 2009).
Conversion of GiPSCs into NS cells enabled us to
assess the functional significance of the widespread re-
setting of aberrations in DNA methylation. Recent stud-
ies using immortalized mouse cells have speculated that
removing DNA methylation from silenced tumor sup-
pressors might restore normal cell cycle control (Ron-
Bigger et al. 2010). However, NS cells generated from
GiPSCs remained highly proliferative both in vitro and
after orthotopic xenotransplantation. Thus, for the GBM
cells analyzed here, reversing a large proportion of DNA
methylation abnormalities did not override the activity
of genetically altered pathways in driving unconstrained
proliferation. Our findings would support a model in
which epigenetic disruptions, such as changes to PRC2
targets, could have important functional roles during
early tumor development (Feinberg et al. 2006), but their
functional importance is diminished as genetic alterations
accumulate.
GBMs are highly diverse in patterns of both genetic and
epigenetic changes, and it will be important to extend
this approach to a larger tumor series. Of interest will be
to study other forms of GBM, particularly secondaryGBM
and pediatric cases, which display epigenetic features
distinct from primary GBM (Schwartzentruber et al. 2012;
Sturm et al. 2012). We investigated those genes that have
beenmost commonly associated with aberrant DNAmeth-
ylation in GBM tumors. However, it should be noted that
Stricker et al.
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Figure 7. GiPSC-derived mesodermal progenitors are no longer infiltrative. (A) Nonneural mesodermal cells (M-iG7-1 and M-iG7-2) were
generated by in vitro differentiation of GiPSCs (P12–P14). Immunocytochemistry for the neural marker BLBP and Nestin and the nonneural
epithelial marker keratins 7 and 8 (CAM5.2) confirms that in contrast to G7, M-iG7 cells show no expression of NS cell markers but partially
express nonneuronal epithelial keratins. (B) Top three gene ontology terms (sorted by odds ratio) for those genes specifically induced in M-iG7
cells after differentiation. (C,D,F) Coronal sections of typical examples of forebrains from mice injected with 100,000 G7 and M-iG7-1 cells
after 18 wk. (IS) Injection site; (CI) contralateral side. M-iG7-1 formed benign, noninfiltrative tumors that lacked pluripotency marker (see
Supplemental Fig. 6E), expressed TES, and stained positive for alcian blue (indicative of cartilage). This contrasted with the highly infiltrative
behavior of G7. See also Figure 6. Ki-67-positive cells were present in the benign mass but rare. (E) Immunoblotting for tumor suppressors,
pluripotency marker NANOG, and radial glia/NS cell marker BLBP. CDKN1C (F) and TES (D) are only detectable in nonneural cultures
(M-iG7-1 and M-iG7-2) or tumors.
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iPSC reprogramming did not fully restore all epigenetic
anomalies. The reprogramming process is also likely to
have reset other types of epigenetic abnormalities that
might have considerable influence on tumorigenicity,
such as histone modifications or noncoding RNAs, and
it will now be of interest to explore these further.
Differentiation of GiPSCs to mesodermal cells enabled
us to test whether the malignant features of G7 are
entirely defined by inherent genetic alterations or could
be reduced by imparting more widespread developmen-
tal epigenetic changes. A defining feature of GBM cells is
their capacity to infiltrate surrounding brain tissue.
Tumors generated following orthotopic xenotransplanta-
tion of mesodermal GiPSC-derived cells showed reduced
capacity to infiltrate surrounding brain tissue. One mo-
lecular explanation for this could be the sustained ex-
pression of CDKN1C and TES within the mesodermal
progenitors. CDKN1C and TES are known regulators of
cell cycle and cell motility, respectively (Pateras et al.
2006; Boeda et al. 2007), and we demonstrated that knock-
down of TES in M-iG7 cells reduces their motility in vitro
(Supplemental Fig. 4C). In NS-like cells derived from the
GiPSCs, expression of CDKN1C and TES were not sus-
tained despite removal of DNA hypermethylation.
In summary, our study demonstrates that highly aneu-
ploid human cancer cells can be reprogrammed to an early
embryonic state with concomitant removal of cancer-
specific DNA methylation marks. By steering these cells
along distinct developmental paths and testing functional
outcomes in vivo, we showed that extensive resetting of
cMVPs alone is not sufficient to suppress malignant
cellular behavior and that there are lineage-specific re-
quirements for sustained expression of tumor suppressor
genes.
Materials and methods
Culture of NS and GNS cell lines
Fetal NS cell lines and GNS lines derived from human glioma
samples have been described previously (Sun et al. 2008; Fael Al-
Mayhani et al. 2009; Pollard et al. 2009;). Briefly, GNS and NS
cells were cultured using serum-free basal medium supple-
mented with B27 and N2 culture supplements (Life Technolo-
gies). Growth factors EGF and FGF-2 (20 ng/mL) were added.
Culture vessels were coated with Laminin (Sigma) at 10 mg/mL
prior to use or during routine passage and was added directly to
the culture medium at 1 mg/mL. GNS cells were routinely grown
to confluence and dissociated using Accutase (Sigma).
iPSCs and hESCs were cultured in DMEM/F-12 supplemented
with nonessential amino acids, 2 mM L-glutamine, 0.1 mM
2-mercaptoethanol, and 20% knockout serum replacement (Life
Technologies). To this, we added FGF-2 (10 ng/mL). Cells were
plated on mitotically inactivated mouse embryonic fibroblasts.
Cells were split every 7–14 d (1:3–1:10) or frozen in clumps using
dissociation buffer (20% KSR, 1 mM CaCl2, 1 mg/mL collage-
nase IV, 0.25% trypsin in PBS) or freezing buffer (2MDMSO, 1M
acetamide, 3 M propylene glycol in ESC medium).
Induced reprogramming and culture of hESCs and iPSCs
Fifteen GNS cell lines were tested for transcription factor-based
reprogramming up to three times (G2, G7, G14, G18, G19, G21,
G23, G25, G26, G30, G32, G144, G166, G179, and G144-D6)
(Supplemental Table S1). The NS cell line CB660 was used in
parallel as a normal control. Cells (2 3 106 to 6 3 106) were
transfected using the Amaxa Nucleofector (Lonza) with 2 mg of
PBhKlf4 and PBhOct4 (see the Supplemental Material) and 4 mg
of the transposase PBase. Cells were seeded on a 10-cm dish
precoated with gelatin (0.1%) and a layer of 2 3 104 mitotically
inactivatedmouse embryonic fibroblasts (hygromycin-resistant).
Three days to 4 d later, 50 mg/mL hygromycin was added for
selection of transfected cells. On day 7, NS cell culture medium
was replaced with iPSC medium. Colonies emerged after 4 wk
and were picked. PiggyBac cassettes were excised from GiPSCs
differentiated progeny following delivery of Cre using adenovi-
rus. Confirmation of excision was possible using the loss of
dsRED expression and lack of OCT4 protein within differenti-
ated cultures and tumors (Fig. 6C; Supplemental Fig. 6B).
RNA processing and microarray hybridization
Cells were dissociated using Accumax (Millipore), and feeder
cells were depleted. RNAwas extracted with Trizol (Invitrogen),
followed by treatment with TURBO DNase (Ambion). RNA
quality was assessed on the Agilent 2100 Bioanalyzer, and
samples were processed for microarray hybridization according
to the GeneChip whole-transcript sense target labeling assay
(Affymetrix). Briefly, 2 mg of each sample was depleted of ribo-
somal RNA (RiboMinus, Invitrogen). Double-stranded cDNAwas
synthesized using random hexamers tagged with a 59 T7 primer,
and the products were amplified with T7 RNA polymerase to
generate antisense cRNA. Reverse transcription was performed
on the cRNA template using SuperScript III to yield ssDNA in
the sense orientation, substituting dUTPs for dTTPs, and the
cRNAwas subsequently degraded via RNase H digestion. cDNA
products were then nicked with uracil DNA glycosylase (UDG)
and apurinic/apyrimidinic endonuclease 1 (APE 1) at sites of
first-strand dUTP incorporation, followed by biotin labeling with
terminal deoxynucleotidyl transferase (TdT). Affymetrix Exon
Array 1.0 ST arrays were hybridized for 16 h at 45°C, washed,
stained with streptavidin-phycoerythrin (SAPE) conjugate on a
FS450 automated fluidics station, and imaged on a GCS3000 7G
scanner (Affymetrix). Feature extraction was performed using
Command Console 3.2.3, and hybridization quality was assessed
with Expression Console 1.1.2 (Affymetrix). Gene expression
analysis, functional category testing, and genome-wide methyl-
ation profiling methods are described in detail in the Supple-
mental Material. Exon array data are available in the ArrayEx-
press repository under accession E-MTAB-1273.
Quantitative real-time PCR
For qRT–PCR, RNA was extracted using RNeasy (Qiagen),
including a DNase digestion step. cDNA was generated using
SuperScript III (Invitrogen), and real-time PCR was carried out
using TLDA microfluidic cards (Applied Biosystems). TaqMan
fast universal PCR master mix was used with primers and
probes as described in the Supplemental Material. TLDA data
were analyzed using the Bioconductor package HTqPCR (Dvinge
and Bertone 2009). PCA was carried out in R using the prcomp
method in the R stats package to compute singular value de-
composition, and results were visualized in OpenGL using RGL.
In vitro differentiation of iPSCs
For mesodermal differentiation, iPSC and GiPSC colonies were
dissociated using Accumax and cultured for 7 d on nonadherent
plates with serum-containing medium (GMEM; 10% fetal calf
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serum, 0.18 mM b-mercaptoethanol supplemented with sodium
pyruvate and nonessential amino acids [Invitrogen]). EBs were
mechanically dissociated and either plated on gelatin-coated
vessels and cultured for an additional 7–10 d in the samemedium
supplemented with retinoid acid (5 nM) and BMP-4 (10 ng/mL)
(EB differentiation) or grown in serum-containing medium until
cultures showed an homogenous epithelial phenotype (M-iG7).
For deriving neural cultures, iPSC and GiPSC colonies were
plated down on Laminin-coated dishes in RHB-A medium until
neuroepithelial rosettes were visible, then passaged once in
RHB-A medium supplemented with EGF and FGF-2 (20 ng/mL)
and either grown as neurospheres in RHB-A (supplemented with
EGF and FGF [20 ng/mL]) or plated onto Laminin-coated dishes
in the samemedium condition (N-iG7). N-iG7 andM-iG7 cultures
were subsequently passaged in RHB-A (supplemented with EGF
and FGF) before experimental analysis.
Xenotransplantation
iPSCs, GiPSCs, and GNS cells were dissociated in clumps
(Accumax), depleted of feeder cells, and diluted in PBS or 10%
Matrigel in PBS, and 50,000 cells were transplanted for kidney
capsule or subcutaneous injection into 6- to 9-wk-old NOD/
SCID immunodeficient mice (NOD.CB17-Prkdcscid/NcrCrl,
Charles River). Parental GNS cells failed to form tumors when
transplanted in kidney capsule (G7, zero of four; G26, zero of
four), but glioma-like tumors emerged using 250,000 cells.
Additionally, 200,000 GiPSC (iG7-2) were injected using a ste-
reotaxic frame into 6- to 8-wk-old NOD/SCID striatum follow-
ing administration of general anesthesia as previously described.
Genomic analysis
GeneChip SNP 6.0 arrays (Affymetrix) were used to determine
genetic alterations. Cells were dissociated, depleted of feeder
cells, and processed using theDNAWizard kit (Promega) to obtain
genomic DNA. Data were analyzed using the Partek Genomics
suite. Changes inDNA copy number were inferred using a hidden
Markov model algorithm. Regions of gain were called using
a threshold of 2.3 copies, and regions of loss were called with a
cutoff at 1.7 copies. Copy number changes were called only when
a minimum of 10 loci were above (or below) the threshold. SNP
array data are available in the ArrayExpress repository under
accession E-MTAB-1271.
Pyrosequencing
One microgram of DNA was bisulfite-treated using EZ DNA
methylation kit (Zymo Research). Bisulfite-treated DNA was
used for generating PCR-amplified templates for pyrosequencing
using target-specific primers (Supplemental Material). Ten mi-
croliters of the biotinylated PCR products were sequenced ac-
cording to the manufacturer’s instructions. Pyrosequencing was
carried on the PSQ HS 96 System and PyroMark MD System
using Pyro Gold reagents (Biotage). Methylation was quantified
using Pyro Q-CpG software that calculates the ratio of converted
C’s (T’s) to unconverted C’s at each CpG and expresses this as
percentage DNAmethylation. Average DNAmethylation across
the target region was determined for each sample and compared
with the Batman and Infinium DNA methylation scores.
Genome-wide methylation profiling
One microgram of DNA was bisulfite-converted using the EZ
DNA methylation kit (Zymo Research). The samples were then
hybridized to Illumina Infinium Human 27K BeadArrays or the
Illumina Infinium Human 450K BeadArrays according to the
manufacturer’s instructions. BeadStudio software (Illumina) was
used to infer methylation scores from image intensities. Meth-
ylation data were quantile-normalized prior to calling MVPs.
Using the distribution of differences between sample meth-
ylation scores, we defined a conservative threshold for calling
differentially methylated regions based on the 95th percentile of
the difference in methylation score. This resulted in a differ-
ence in methylation score of 31% between samples being
considered as differentially methylated. PRC2 gene lists were
defined from the gene set enrichment analysis database. Pri-
mary GBM 450K array methylation data were downloaded
from the TCGA data portal (https://tcga-data.nci.nih.gov/tcga).
Survival analysis was performed on 67 patients with a median
survival of 202 d using the R package survival. Data for DNA
methylation of GNS cells and reprogrammed derivatives are
available in the ArrayExpress repository under accessions
E-MTAB-1274 (450K arrays) and E-MTAB-1275 (27K arrays).
Immunocytochemistry
Cells in culture were fixed in 4% paraformaldehyde (PFA) for 10
min, washed three times in PBST, and transferred to blocking
solution (3% goat serum, 1%BSA in PBST). Primary (listed in the
Supplemental Material) and secondary antibodies were diluted
in blocking solution, incubated overnight at 4°C and 2 h at room
temperature, respectively, and separated by three washings.
DAPI (0.5 ug/mL) was used to visualize nuclei.
Immunoblotting
Immunoblotting was performed using standard protocols, anti-
bodies were diluted in 5% milk powder in PBST, and protein
detection was carried out with HRP-coupled secondary anti-
bodies and X-ray films.
Immunohistochemistry
Tumors were fixed between 12 and 24 h in 4% PFA embedded in
paraffin and sectioned using a microtome (5–10 mm). Heat-
induced epitope retrieval for 20 or 40 min in 10 mmol/L citrate
buffer (pH 6) was used for CEA (M7072, Dako) or S100 (z0311,
Dako) immunostaining. Primary antibodies were diluted 1:200
(S100), 1:25 (CEA), or 1:1 (CAM5.2, BD Biosciences). The Dako
Envision HRP kit or biotin/avidin horseradish peroxidize pro-
cedure was used according to the manufacturers’ protocols to
visualize antibody binding. For fluorescent immunohistochem-
istry, sections were rehydrated using standard protocols (23
xylene for 15 min, 100% 33 ethanol for 10 min, 70% ethanol
for 10 min). Epitope retrieval was performed in 10 mmol/L
citrate buffer (pH 6) using a pressure cooker. Primary and
secondary antibodies were diluted in 5% goat serum (diluted in
PBST). For analysis of KI-67 immunoreactivity, at least three
regions with highest, medium, and lowest KI-67 immunoreac-
tivity in each section were analyzed. At least 33 85 nuclei were
counted for each class and cell line. Error bars depict the standard
deviation. Standard histochemical protocols were used for
haematoxylin, alcian blue, and eosin staining.
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